Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models

Copanlisib is a pan–class I phosphoinositide 3-kinase (PI3K) inhibitor with preferred activity toward PI3Kα and PI3Kδ. Despite the clear overall clinical benefit, the number of patients achieving complete remissions with the single agent is relatively low, a problem shared by the vast majority of ta...

全面介紹

Na minha lista:
書目詳細資料
發表在:Blood Adv
Main Authors: Tarantelli, Chiara, Lange, Martin, Gaudio, Eugenio, Cascione, Luciano, Spriano, Filippo, Kwee, Ivo, Arribas, Alberto J., Rinaldi, Andrea, Jourdan, Thibaud, Berthold, Melanie, Sturz, Andrea, Sperl, Carolyn, Margheriti, Francesco, Scalise, Lorenzo, Gritti, Giuseppe, Rossi, Davide, Stathis, Anastasios, Liu, Ningshu, Zucca, Emanuele, Politz, Oliver, Bertoni, Francesco
格式: Artigo
語言:Inglês
出版: American Society of Hematology 2020
主題:
Lymphoid Neoplasia
在線閱讀:https://ncbi.nlm.nih.gov/pmc/articles/PMC7065481/
https://ncbi.nlm.nih.gov/pubmed/32126142
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000844
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!

相似書籍